Skip to content

Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer

Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer - JBCRG-C06

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000015168
Enrollment
1000
Registered
2014-09-16
Start date
2014-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with postmenopausal ER-positive advanced recurrent breast cancer

Interventions

None listed

Sponsors

Japan Breast Cancer Research Group(JBCRG)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1)Patients not agree with this study

Design outcomes

Primary

MeasureTime frame
Effects of clinical background and prior therapies on the treatment time with Fulvestrant (TTF)

Secondary

MeasureTime frame
Secondary analysis 1.Effects of clinical background and prior therapies on overall survival (OS) after start of Fulvestrant 2.Descriptive statistics of treatment 3.Summary of therapies administered to subjects with long survival

Countries

Japan

Contacts

Public ContactKatsumasa Kuroi

Japan Breast Cancer Research Group (JBCRG) Adminstrative office

office@jbcrg.jp03-6264-8873

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026